Is Sawai Heading For A Cash Creation Crisis?
Flurry Of Headwinds In Japan And US, Not Least Pricing And Continued Investments
Three quarters of the way through its financial year, Sawai has half as much cash on its balance sheet as it did at the same stage in 2021/22, as the Japanese firm continues to be dogged by lower government-mandated prices and higher costs at home.
You may also be interested in...
Plummeting sales and profit following government price regulations pushes Chemiphar to target international expansion
The impact of drug shortages in Japan, including of essential products, is being considered as part of government-level discussions to consider the appropriateness of the current reimbursement pricing system. Amid rising production costs and wider global challenges, some experts in the industry are now asking for price increases.
Sawai was strong in Japan and weak in the US in the first financial quarter of its 2022 financial year, as analysts called on the Japanese firm to improve supply capacity as a “crucial first step towards expanding market share.”